|
|
高危型HPV基因型与宫颈癌的流行病学特征及防控策略
|
Abstract:
高危型人乳头瘤病毒(HPV)感染是宫颈癌发生的主要致病因素，尤其是HPV16和HPV18型与宫颈癌的发生密切相关。本文综述了高危型HPV的流行病学特征，分析了不同地区和人群中HPV基因型的分布及其易感性差异。HPV疫苗接种和宫颈癌筛查是预防HPV感染、减少宫颈癌发生的主要策略。全球范围内HPV疫苗的推广显著降低了高危型HPV感染的流行率，对宫颈癌防治具有重要意义。此外，本文还强调了在高危人群中开展早期筛查和定期干预的重要性，突出了这些措施在促进早期诊断和减少疾病负担方面的积极作用。
High-risk human papillomavirus (HPV) infection is the main cause of cervical cancer, with HPV types 16 and 18 being particularly closely linked to its development. This review explores the epidemiology of high-risk HPV, focusing on the distribution of HPV genotypes and variations in susceptibility across different regions and populations. HPV vaccination and cervical cancer screening are the primary strategies for preventing HPV infections and reducing the incidence of cervical cancer. The global expansion of HPV vaccination has significantly reduced the prevalence of high-risk HPV infections, with important implications for cervical cancer prevention and control. Furthermore, this review emphasizes the critical role of early screening and regular interventions in high-risk groups, highlighting their impact on improving early diagnosis and reducing the overall disease burden.
| [1] | International Agency for Research on Cancer (2024) Globocan 2022: Cancer Today. International Agency for Research on Cancer. https://gco.iarc.fr/today |
| [2] | Walboomers, J.M.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., et al. (1999) Human Papillomavirus Is a Necessary Cause of Invasive Cervical Cancer Worldwide. The Journal of Pathology, 189, 12-19. https://doi.org/10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f |
| [3] | zur Hausen, H., Meinhof, W., Scheiber, W. and Bornkamm, G.W. (1974) Attempts to Detect Virus-Specific DNA in Human Tumors. I. Nucleic Acid Hybridizations with Complementary RNA of Human Wart Virus. International Journal of Cancer, 13, 650-656. https://doi.org/10.1002/ijc.2910130509 |
| [4] | zur Hausen, H. (1976) Condylomata Acuminata and Human Genital Cancer. Cancer Research, 36, Article 794. |
| [5] | Schwarz, E., Freese, U.K., Gissmann, L., Mayer, W., Roggenbuck, B., Stremlau, A., et al. (1985) Structure and Transcription of Human Papillomavirus Sequences in Cervical Carcinoma Cells. Nature, 314, 111-114. https://doi.org/10.1038/314111a0 |
| [6] | zur Hausen, H. (1988) Papillomaviruses in Human Cancers. Molecular Carcinogenesis, 1, 147-150. https://doi.org/10.1002/mc.2940010302 |
| [7] | de Martel, C., Plummer, M., Vignat, J. and Franceschi, S. (2017) Worldwide Burden of Cancer Attributable to HPV by Site, Country and HPV Type. International Journal of Cancer, 141, 664-670. https://doi.org/10.1002/ijc.30716 |
| [8] | Muñoz, N., Bosch, F.X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K.V., et al. (2003) Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. New England Journal of Medicine, 348, 518-527. https://doi.org/10.1056/nejmoa021641 |
| [9] | Yang, X., Li, Y., Tang, Y., Li, Z., Wang, S., Luo, X., et al. (2023) Cervical HPV Infection in Guangzhou, China: An Epidemiological Study of 198,111 Women from 2015 to 2021. Emerging Microbes & Infections, 12, e21760009. https://doi.org/10.1080/22221751.2023.2176009 |
| [10] | de Martel, C., Georges, D., Bray, F., Ferlay, J. and Clifford, G.M. (2020) Global Burden of Cancer Attributable to Infections in 2018: A Worldwide Incidence Analysis. The Lancet Global Health, 8, e180-e190. https://doi.org/10.1016/s2214-109x(19)30488-7 |
| [11] | Markowitz, L.E. and Unger, E.R. (2023) Human Papillomavirus Vaccination. New England Journal of Medicine, 388, 1790-1798. https://doi.org/10.1056/nejmcp2108502 |
| [12] | World Health Organization (2020) Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. https://www.who.int/publications/i/item/9789240014107 |
| [13] | Zhang, J., Zha, T., Wang, X. and He, W. (2024) Prevalence and Genotype Distribution of HPV Infections among Women in Chengdu, China. Virology Journal, 21, Article No. 52. https://doi.org/10.1186/s12985-024-02317-x |
| [14] | Bruni, L., Diaz, M., Castellsagué, X., Ferrer, E., Bosch, F.X. and de Sanjosé, S. (2010) Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings. The Journal of Infectious Diseases, 202, 1789-1799. https://doi.org/10.1086/657321 |
| [15] | Wu, E., Liu, B., Cui, J., Chen, W., Wang, J., Lu, L., et al. (2013) Prevalence of Type-Specific Human Papillomavirus and Pap Results in Chinese Women: A Multi-Center, Population-Based Cross-Sectional Study. Cancer Causes & Control, 24, 795-803. https://doi.org/10.1007/s10552-013-0162-8 |
| [16] | Tota, J.E., Chevarie-Davis, M., Richardson, L.A., de Vries, M. and Franco, E.L. (2011) Epidemiology and Burden of HPV Infection and Related Diseases: Implications for Prevention Strategies. Preventive Medicine, 53, S12-S21. https://doi.org/10.1016/j.ypmed.2011.08.017 |
| [17] | González, P., Hildesheim, A., Rodríguez, A.C., Schiffman, M., Porras, C., Wacholder, S., et al. (2010) Behavioral/Lifestyle and Immunologic Factors Associated with HPV Infection among Women Older Than 45 Years. Cancer Epidemiology, Biomarkers & Prevention, 19, 3044-3054. https://doi.org/10.1158/1055-9965.epi-10-0645 |
| [18] | Moscicki, A. (2001) Risks for Incident Human Papillomavirus Infection and Low-Grade Squamous Intraepithelial Lesion Development in Young Females. Journal of the American Medical Association, 285, Article 2995. https://doi.org/10.1001/jama.285.23.2995 |
| [19] | Zhao, F., Lewkowitz, A.K., Hu, S., Chen, F., Li, L., Zhang, Q., et al. (2012) Prevalence of Human Papillomavirus and Cervical Intraepithelial Neoplasia in China: A Pooled Analysis of 17 Population-Based Studies. International Journal of Cancer, 131, 2929-2938. https://doi.org/10.1002/ijc.27571 |
| [20] | Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., et al. (2024) Cancer Incidence and Mortality in China, 2022. Journal of the National Cancer Center, 4, 47-53. https://doi.org/10.1016/j.jncc.2024.01.006 |
| [21] | Wolf, J., Kist, L.F., Pereira, S.B., Quessada, M.A., Petek, H., Pille, A., et al. (2024) Human Papillomavirus Infection: Epidemiology, Biology, Host Interactions, Cancer Development, Prevention, and Therapeutics. Reviews in Medical Virology, 34, e2537. https://doi.org/10.1002/rmv.2537 |
| [22] | Stefanos, R., Lewis, R.M., Querec, T.D., Gargano, J.W., Unger, E.R. and Markowitz, L.E. (2024) High Impact of Quadrivalent Human Papillomavirus Vaccine across Racial/Ethnic Groups: National Health and Nutrition Examination Survey, 2003-2006 and 2015-2018. Human Vaccines & Immunotherapeutics, 20, Article 2308378. https://doi.org/10.1080/21645515.2024.2308378 |
| [23] | Palmer, T.J., Kavanagh, K., Cuschieri, K., Cameron, R., Graham, C., Wilson, A., et al. (2024) Invasive Cervical Cancer Incidence Following Bivalent Human Papillomavirus Vaccination: A Population-Based Observational Study of Age at Immunization, Dose, and Deprivation. Journal of the National Cancer Institute, 116, 857-865. https://doi.org/10.1093/jnci/djad263 |
| [24] | Palmer, T., Wallace, L., Pollock, K.G., Cuschieri, K., Robertson, C., Kavanagh, K., et al. (2019) Prevalence of Cervical Disease at Age 20 after Immunisation with Bivalent HPV Vaccine at Age 12-13 in Scotland: Retrospective Population Study. British Medical Journal, 365, Article 11161. https://doi.org/10.1136/bmj.l1161 |
| [25] | Malagón, T., Franco, E.L., Tejada, R. and Vaccarella, S. (2024) Epidemiology of HPV-Associated Cancers Past, Present and Future: Towards Prevention and Elimination. Nature Reviews Clinical Oncology, 21, 522-538. https://doi.org/10.1038/s41571-024-00904-z |
| [26] | Schiller, J.T., Castellsagué, X. and Garland, S.M. (2012) A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine, 30, F123-F138. https://doi.org/10.1016/j.vaccine.2012.04.108 |
| [27] | Villa, L.L., Costa, R.L.R., Petta, C.A., Andrade, R.P., Paavonen, J., Iversen, O., et al. (2006) High Sustained Efficacy of a Prophylactic Quadrivalent Human Papillomavirus Types 6/11/16/18 L1 Virus-Like Particle Vaccine through 5 Years of Follow-Up. British Journal of Cancer, 95, 1459-1466. https://doi.org/10.1038/sj.bjc.6603469 |
| [28] | Kjaer, S.K., Nygård, M., Sundström, K., Munk, C., Berger, S., Dzabic, M., et al. (2020) Long-Term Effectiveness of the Nine-Valent Human Papillomavirus Vaccine in Scandinavian Women: Interim Analysis after 8 Years of Follow-Up. Human Vaccines & Immunotherapeutics, 17, 943-949. https://doi.org/10.1080/21645515.2020.1839292 |
| [29] | Curry, S.J., Krist, A.H., Owens, D.K., Barry, M.J., Caughey, A.B., Davidson, K.W., et al. (2018) Screening for Cervical Cancer. Journal of the American Medical Association, 320, 674-686. https://doi.org/10.1001/jama.2018.10897 |
| [30] | Workowski, K.A., Bachmann, L.H., Chan, P.A., Johnston, C.M., Muzny, C.A., Park, I., et al. (2021) Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and Reports, 70, 1-187. https://doi.org/10.15585/mmwr.rr7004a1 |
| [31] | Abraham, A.G., D’Souza, G., Jing, Y., Gange, S.J., Sterling, T.R., Silverberg, M.J., et al. (2013) Invasive Cervical Cancer Risk among HIV-Infected Women. JAIDS Journal of Acquired Immune Deficiency Syndromes, 62, 405-413. https://doi.org/10.1097/qai.0b013e31828177d7 |
| [32] | McClymont, E., Lee, M., Raboud, J., Coutlée, F., Walmsley, S., Lipsky, N., et al. (2020) Prevalent and Persistent Oncogenic HPV Types in a Cohort of Women Living with HIV Prior to HPV Vaccination. International Journal of Gynecology & Obstetrics, 150, 108-115. https://doi.org/10.1002/ijgo.13185 |
| [33] | Massad, L.S., Xie, X., Burk, R.D., D’Souza, G., Darragh, T.M., Minkoff, H., et al. (2016) Association of Cervical Precancer with Human Papillomavirus Types Other than 16 among HIV Co-Infected Women. American Journal of Obstetrics and Gynecology, 214, 354.e1-354.e6. https://doi.org/10.1016/j.ajog.2015.09.086 |
| [34] | Clifford, G.M., Gonçalves, M.A.G. and Franceschi, S. (2006) Human Papillomavirus Types among Women Infected with HIV: A Meta-Analysis. AIDS, 20, 2337-2344. https://doi.org/10.1097/01.aids.0000253361.63578.14 |
| [35] | Paavonen, J., Naud, P., Salmerón, J., et al. (2009) Efficacy of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine against Cervical Infection and Precancer Caused by Oncogenic HPV Types (Patricia): Final Analysis of a Double-Blind, Randomized Study in Young Women. Lancet (London, England), 374, 301-314. https://doi.org/10.1016/s0140-6736(09)61248-4 |
| [36] | Garland, S.M., Hernandez-Avila, M., Wheeler, C.M., Perez, G., Harper, D.M., Leodolter, S., et al. (2007) Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine, 356, 1928-1943. https://doi.org/10.1056/nejmoa061760 |
| [37] | Lv, H., Wang, S., Liang, Z., Yu, W., Yan, C., Chen, Y., et al. (2022) Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Chinese Females 9-45 Years of Age: A Phase 3 Open-Label Study. Vaccine, 40, 3263-3271. https://doi.org/10.1016/j.vaccine.2022.02.061 |
| [38] | Qiao, Y., Wu, T., Li, R., Hu, Y., Wei, L., Li, C., et al. (2019) Efficacy, Safety, and Immunogenicity of an Escherichia Coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. Journal of the National Cancer Institute, 112, 145-153. https://doi.org/10.1093/jnci/djz074 |
| [39] | Zhu, F., Li, C., Pan, H., Zhang, Y., Bi, D., Tang, H., et al. (2011) Safety and Immunogenicity of Human Papillomavirus-16/18 As04-Adjuvanted Vaccine in Healthy Chinese Females Aged 15 to 45 Years: A Phase I Trial. Chinese Journal of Cancer, 30, 559-564. https://doi.org/10.5732/cjc.010.10564 |
| [40] | Zhao, F., Wu, T., Hu, Y., Wei, L., Li, M., Huang, W., et al. (2022) Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Human Papillomavirus (16 and 18) L1 Virus-Like-Particle Vaccine: End-of-Study Analysis of a Phase 3, Double-Blind, Randomized, Controlled Trial. The Lancet Infectious Diseases, 22, 1756-1768. https://doi.org/10.1016/s1473-3099(22)00435-2 |
| [41] | Bruni, L., Albero, G., Rowley, J., Alemany, L., Arbyn, M., Giuliano, A.R., et al. (2023) Global and Regional Estimates of Genital Human Papillomavirus Prevalence among Men: A Systematic Review and Meta-Analysis. The Lancet Global Health, 11, e1345-e1362. https://doi.org/10.1016/s2214-109x(23)00305-4 |
| [42] | Giuliano, A.R., Palefsky, J.M., Goldstone, S., Moreira, E.D., Penny, M.E., Aranda, C., et al. (2011) Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. New England Journal of Medicine, 364, 401-411. https://doi.org/10.1056/nejmoa0909537 |
| [43] | Arbyn, M., Castellsagué, X., de Sanjosé, S., Bruni, L., Saraiya, M., Bray, F., et al. (2011) Worldwide Burden of Cervical Cancer in 2008. Annals of Oncology, 22, 2675-2686. https://doi.org/10.1093/annonc/mdr015 |
| [44] | Andrae, B., Kemetli, L., Sparen, P., Silfverdal, L., Strander, B., Ryd, W., et al. (2008) Screening-Preventable Cervical Cancer Risks: Evidence from a Nationwide Audit in Sweden. Journal of the National Cancer Institute, 100, 622-629. https://doi.org/10.1093/jnci/djn099 |
| [45] | Canfell, K., Kim, J.J., Brisson, M., Keane, A., Simms, K.T., Caruana, M., et al. (2020) Mortality Impact of Achieving WHO Cervical Cancer Elimination Targets: A Comparative Modelling Analysis in 78 Low-Income and Lower-Middle-Income Countries. The Lancet, 395, 591-603. https://doi.org/10.1016/s0140-6736(20)30157-4 |
| [46] | Brisson, M., Kim, J.J., Canfell, K., Drolet, M., Gingras, G., Burger, E.A., et al. (2020) Impact of HPV Vaccination and Cervical Screening on Cervical Cancer Elimination: A Comparative Modelling Analysis in 78 Low-Income and Lower-Middle-Income Countries. The Lancet, 395, 575-590. https://doi.org/10.1016/s0140-6736(20)30068-4 |
| [47] | Ji, X., Hao, M., Wang, Y., Pan, Z., Yang, R., Wang, X., et al. (2024) HPV Self-Sampling for Cervical Cancer Screening in China: A Multi-Center Study. Heliyon, 10, e39544. https://doi.org/10.1016/j.heliyon.2024.e39544 |
| [48] | Koliopoulos, G., Nyaga, V.N., Santesso, N., Bryant, A., Martin-Hirsch, P.P., Mustafa, R.A., et al. (2017) Cytology versus HPV Testing for Cervical Cancer Screening in the General Population. Cochrane Database of Systematic Reviews, 2018, CD008587. https://doi.org/10.1002/14651858.cd008587.pub2 |
| [49] | Cuzick, J., Clavel, C., Petry, K., Meijer, C.J.L.M., Hoyer, H., Ratnam, S., et al. (2006) Overview of the European and North American Studies on HPV Testing in Primary Cervical Cancer Screening. International Journal of Cancer, 119, 1095-1101. https://doi.org/10.1002/ijc.21955 |
| [50] | Benevolo, M., Ronco, G., Mancuso, P., et al. (2024) Comparison of HPV-Positive Triage Strategies Combining Extended Genotyping with Cytology or P16/KI67 Dual Staining in the Italian NTCC2 Study. E BioMedicine, 104, Article 105149. https://doi.org/10.1016/j.ebiom.2024.105149 |
| [51] | Liang, L.A., Einzmann, T., Franzen, A., Schwarzer, K., Schauberger, G., Schriefer, D., et al. (2021) Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-Alone or Cotesting Strategies. Cancer Epidemiology, Biomarkers & Prevention, 30, 474-484. https://doi.org/10.1158/1055-9965.epi-20-1003 |
| [52] | Wright, T.C., Stoler, M.H., Behrens, C.M., Sharma, A., Zhang, G. and Wright, T.L. (2015) Primary Cervical Cancer Screening with Human Papillomavirus: End of Study Results from the ATHENA Study Using HPV as the First-Line Screening Test. Gynecologic Oncology, 136, 189-197. https://doi.org/10.1016/j.ygyno.2014.11.076 |
| [53] | Bulkmans, N., Berkhof, J., Rozendaal, L., van Kemenade, F., Boeke, A., Bulk, S., et al. (2007) Human Papillomavirus DNA Testing for the Detection of Cervical Intraepithelial Neoplasia Grade 3 and Cancer: 5-Year Follow-Up of a Randomized Controlled Implementation Trial. The Lancet, 370, 1764-1772. https://doi.org/10.1016/s0140-6736(07)61450-0 |
